EQS-Adhoc: RHÖN-KLINIKUM Aktiengesellschaft adjusts the EBITDA forecast for financial year 2025
|
EQS-Ad-hoc: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Change in Forecast Ad hoc announcement pursuant to Article 17 MAR RHÖN-KLINIKUM Aktiengesellschaft Schlossplatz 1 97616 Bad Neustadt a. d. Saale ISIN DE0007042301 / WKN 704230 Bad Neustadt a. d. Saale | 14 January 2026
RHÖN-KLINIKUM Aktiengesellschaft adjusts the EBITDA forecast for the financial year 2025 RHÖN-KLINIKUM Aktiengesellschaft announces that the Group's projected EBITDA (earnings before interest, taxes, depreciation, and amortization – as defined on page 35 of the Annual Report 2024) for the financial year 2025 will likely not be achieved. Due to unforeseen business developments, the Company now expects, based on preliminary and unaudited figures that still need to be consolidated at Group level, an EBITDA in the range of EUR 100 million to EUR 105 million, instead of the previously projected EBITDA between EUR 110 million and EUR 125 million. The management board maintains its forecast for the past financial year with regard to the other key performance indicators. The preliminary and unaudited figures available to the management board indicate that the expected effects from the refinancing of increased personnel and material costs for the provision of hospital services, such as immediate transformation costs, and the planned agreement with health insurance companies regarding legacy cases, will only have a delayed impact. The publication of the annual report for the financial year 2025 is planned for 26 March 2026.
RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 913,000 patients are treated at our five sites of Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,700 persons. The innovative RHÖN Campus approach for cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with ASKLEPIOS are important elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com
Contact: RHÖN-KLINIKUM AG | Head of Group Finance Norman Dittes | T. +49 9771 65-12210 | norman.dittes@rhoen-klinikum-ag.de RHÖN-KLINIKUM AG | Schlossplatz 1 | 97616 Bad Neustadt a. d. Saale End of Inside Information
14-Jan-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | RHÖN-KLINIKUM Aktiengesellschaft |
| Salzburger Leite 1 | |
| 97616 Bad Neustadt a. d. Saale | |
| Germany | |
| Phone: | +49 (0)9771 - 65-0 |
| Fax: | +49 (0)9771 - 97 467 |
| E-mail: | rka@rhoen-klinikum-ag.com |
| Internet: | www.rhoen-klinikum-ag.com |
| ISIN: | DE0007042301 |
| WKN: | 704230 |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2260068 |
| End of Announcement | EQS News Service |
|
|
2260068 14-Jan-2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | ||
| Sales1 | 1.360,16 | 1.402,01 | 1.446,09 | 1.463,98 | 1.595,62 | 1.700,00 | 0,00 | |
| EBITDA1,2 | 80,23 | 101,16 | 105,65 | 105,88 | 110,77 | 103,00 | 0,00 | |
| EBITDA-Margin3 | 5,90 | 7,22 | 7,31 | 7,23 | 6,94 | 6,06 | 0,00 | |
| EBIT1,4 | 10,60 | 30,52 | 36,11 | 40,40 | 48,15 | 42,00 | 0,00 | |
| EBIT-Margin5 | 0,78 | 2,18 | 2,50 | 2,76 | 3,02 | 2,47 | 0,00 | |
| Net Profit (Loss)1 | 2,46 | 30,23 | 26,94 | 40,17 | 45,21 | 38,00 | 0,00 | |
| Net-Margin6 | 0,18 | 2,16 | 1,86 | 2,74 | 2,83 | 2,24 | 0,00 | |
| Cashflow1,7 | 113,30 | 97,50 | 41,30 | 109,00 | 127,60 | 110,00 | 0,00 | |
| Earnings per share8 | 0,02 | 0,42 | 0,38 | 0,58 | 0,65 | 0,56 | 0,70 | |
| Dividend per share8 | 0,00 | 0,00 | 0,15 | 0,00 | 0,10 | 0,10 | 0,15 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Rhön-Klinikum | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 704230 | DE0007042301 | AG | 883,91 Mio € | 19.06.1991 | Halten | 9F2G86FM+GX |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 16,92 | 26,47 | 0,64 | 23,91 | 0,69 | 6,93 | 0,55 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,10 | 0,10 | 0,76% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 27.05.2026 | 07.05.2026 | 06.08.2026 | 05.11.2026 | 26.03.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +4,97% | +6,16% | +3,94% | -10,20% | +428,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
